Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Cyprotex Adds In Vitro Toxicology Services

Cyprotex PLC ("Cyprotex" or "the Company")

Cyprotex PLC (LSE:CRX), the preclinical ADME Tox services company, today announces the launch of its new in vitro toxicology service, branded as Cyprotox®. Supporting the new service is an additional 90 square metres of laboratory space at Cyprotex’s Macclesfield, UK facility housing the latest technology in multi-parametric automated fluorescent imaging and cellular analysis. This gives Cyprotex’s Macclesfield site the same in vitro toxicology capabilities as those of Apredica (Watertown, MA, USA), which Cyprotex acquired on 6 August 2010.

The new facility includes a Thermo Scientific Cellomics ArrayScan® VTI HCS Reader, which complements the four Cellomics HCS instruments used at Apredica. The ArrayScan® utilises High Content Screening (HCS) technology to determine multi-parametric indicators of toxicity. HCS is a recent breakthrough for early toxicology assessment. It has been extensively validated, and is now being adopted throughout the pharmaceutical industry.

In addition to HCS, the new facility offers many other services to assess toxicity, including:

• reactive metabolite detection
• mitochondrial toxicity;
• hERG inhibition;
• toxicological gene regulation;
• phospholipidosis;
• phototoxicity;
• haemolysis;
• genotoxicity; and
• a full spectrum of drug-drug interaction assays.

Dr Anthony Baxter, Cyprotex’s Chief Executive Officer, comments on the launch of the new toxicology facility.

“Drug toxicity, and drug-induced liver injury in particular, is a major reason for failures in clinical trials and for the withdrawal of previously approved drugs from the market. Toxicity is the most costly problem in drug development today. Identifying potential liabilities at an early stage in drug discovery decreases the likelihood of late-stage failures, and promises to produce the same magnitude of drug development efficiency improvements that preclinical ADME has provided.

“Cyprotex’s new toxicology facility complements our existing ADME business, and it aligns the capabilities of our UK facility with those of Apredica’s US facility, which Cyprotex acquired earlier this month. The combination of in vitro ADME, in vitro toxicology, and Cyprotex’s proprietary predictive modeling and proprietary CellCiphrTM technology acquired from Cellumen gives Cyprotex’s customers access to the most extensive and advanced portfolio of early ADME Tox services on the market today.”

Enquiries:

Cyprotex PLC
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
Tel: +44 (0) 1625 505 100
ir@cyprotex.com
www.cyprotex.com

Singer Capital Markets Limited (broker to Cyprotex)
Tel: +44 (0) 203 205 7500
Shaun Dobson
shaun.dobson@singercm.com
Claes Spang
claes.spang@singercm.com
www.singercm.com

Financial Dynamics
Tel: +44 (0) 20 7831 3113
Ben Brewerton
Ben Atwell
Mo Noonan
cyprotex@fd.com
www.fd.com

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close